Abstracts Archive - Page 2083 of 2607 - ACR Meeting Abstracts

Abstract Number: 2252 • 2014 ACR/ARHP Annual Meeting
Autoimmune Thyroid Disease Is Associated with a Higher Frequency of Spinal Degenerative Disc Disease
Asha Shrestha¹, Hillel Cohen² and Clement Tagoe¹, ¹Rheumatology, Albert Einstein College of Medicine, Bronx, NY, Bronx, NY, ²Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY, Bronx, NY
Background/Purpose: Autoimmune thyroid disease (AITD) has been linked to a number of rheumatic syndromes including arthritis and generalized pain. Although AITD has been associated with…
Abstract Number: 2253 • 2014 ACR/ARHP Annual Meeting
Effect of Teriparatide in Patients with Osteoporosis with Prior Vertebral Fracture
Guillermo Valenzuela¹, Douglas Yim², Douglas Beall³, Michael Gordon⁴, John H. Krege⁵ and Kelly D. Krohn⁶, ¹Integral Rheumatology and Immunology Specialists, Plantation, FL, ²Division of Vascular & Interventional Radiology, University of California, Irvine Medical Center, Orange, California, Orange, CA, ³Clinical Radiology of Oklahoma, Edmond, Oklahoma, Edmonda, OK, ⁴Newport Orthopedic Institute, Newport Beach, California, Newport Beach, CA, ⁵Eli Lilly and Company, LLC, Indianapolis, Indiana, Indianapolis, IN, ⁶DC 5208, Eli Lilly and Company, LLC, Indianapolis, Indiana, Indianapolis, IN
Background/Purpose: The Direct Assessment of Nonvertebral Fracture in Community Experience (DANCE) study was an open-label, prospective, observational study that examined occurrence of nonvertebral fragility fractures…
Abstract Number: 2254 • 2014 ACR/ARHP Annual Meeting
Changes in Subject Characteristics in the Denosumab Pivotal Fracture Trial and Its Extension for up to 8 Years
JD Adachi¹, CJF Lin², PR Ho², MA Bolognese³, HG Bone⁴, P Hadji⁵, S Papapoulos⁶, C Recknor⁷, NS Daizadeh², P Dakin², RB Wagman² and S Ferrari⁸, ¹McMaster University, Hamilton, ON, Canada, ²Amgen Inc., Thousand Oaks, CA, ³Bethesda Health Research Center, Bethesda, MD, ⁴Michigan Bone and Mineral Clinic, Detroit, MI, ⁵Philipps-University of Marburg, Marburg, Germany, ⁶Leiden University Medical Center, Leiden, Netherlands, ⁷United Osteoporosis Centers, Gainesville, GA, ⁸Geneva University Hospital, Geneva, Switzerland
Background/Purpose: Changes in demographics of study population enrolled in long-term osteoporosis clinical trials may affect interpretation of efficacy/safety outcomes. Denosumab is being evaluated for up…
Abstract Number: 2255 • 2014 ACR/ARHP Annual Meeting
Vertebral Cortical Bone Mass and Structure Significantly Improved with Romosozumab Compared with Teriparatide: HR-QCT Analyses of Postmenopausal Women with Low BMD from a Phase 2 Study
T Damm¹, C Libanati², J Peña¹, G Campbell¹, R Barkmann¹, DA Hanley³, S Goemaere⁴, MA Bolognese⁵, C Recknor⁶, C Mautalen⁷, YC Yang² and CC Glüer¹, ¹Christian-Albrechts-Universität zu Kiel, Kiel, Germany, ²Amgen Inc., Thousand Oaks, CA, ³University of Calgary, Calgary, AB, Canada, ⁴Ghent University Hospital, Ghent, Belgium, ⁵Bethesda Health Research Center, Bethesda, MD, ⁶United Osteoporosis Centers, Gainesville, GA, ⁷Centro de Osteopatias Medicas, Buenos Aires, Argentina
Background/Purpose : Understanding the effect of therapies in the vertebral compartments is relevant to bone biology and clinical practice. We developed an improved technique using…
Abstract Number: 2256 • 2014 ACR/ARHP Annual Meeting
Effects of Pre-Dosage Alendronate Treatment on Bone Metabolic Indices and Bone Mineral Density in Patients Treated with Glucocorticoids: A Prospective Study
Yasuo Kuroki¹, Hiroshi Kaji², Mika Yamauchi³ and Toshitsugu Sugimoto⁴, ¹Dept of Internal Medicine, Kobe Century Memorial Hospital, Kobe, Japan, ²Department of Physiology and Regenerative Medicine, Kinki University Faculty of Medicine, Osakasayama, Japan, ³Internal Medicine 1, Shimane University Faculty of Medicine, Izmo, Japan, ⁴Internal Medicine 1, Shimane University Faculty of Medicine, Izumo, Japan
Background/Purpose: Glucocorticoids (GCs) treatment induces secondary osteoporosis characterized by rapid bone loss and an increase in fracture risk, although GCs are used to treat a…
Abstract Number: 2257 • 2014 ACR/ARHP Annual Meeting
How Does Non-Compliance to Prolia ® (DENOSUMAB) Impact the Change in Bone Mineral Density (BMD) in Osteoporotic Patients?
Aashish Kalani¹, Matt Wong-Pack¹, Jacob Hordyk², Arthur N. Lau³, George Ioannidis⁴, Robert Bensen⁵, William G. Bensen⁶ and Jonathan D. Adachi¹, ¹McMaster University, Hamilton, ON, Canada, ²University of Ottawa, Hamilton, ON, Canada, ³Rheumatology and Clinical Epidemiology, Division of Rheumatology, McMaster University, Hamilton, ON, Canada, ⁴St Joseph's Healthcare Hamilton, Hamilton, ON, Canada, ⁵Rheumatology Health Team, Dr. Bensen's Rheumatology Clinic, Hamilton, ON, Canada, ⁶Department of Medicine, Division of Rheumatology, Clinical Professor, McMaster University, Hamilton, ON, Canada
Background/Purpose: Denosumab (Prolia®) has shown to be a safe and efficacious therapy for osteoporotic patients in many clinical trials. Unfortunately, few studies have explored its effectiveness…
Abstract Number: 2259 • 2014 ACR/ARHP Annual Meeting
Changes in serum Soluble RANKL and Osteoprotegerin Levels after Teriparatide Administration in Rheumatic Disease Patients with Glucocorticoid-Induced Osteoporosis
Makoto Kaburaki, Kaichi Kaneko, Kotaro Shikano, Mai Kawazoe, Emiko Shindo, Hiroshi Sato, Natsuki Fujio, Sei Muraoka, Nahoko Tanaka, Tatsuhiro Yamamoto, Natsuko Kusunoki, Tomoko Hasunuma, Shinichi Kawai and Shotaro Masuoka, Division of Rheumatology, Department of Internal Medicine, School of Medicine, Faculty of Medicine, Toho University, Tokyo, Japan
Background/Purpose ,Osteoporosis is one of the serious complications of systemic glucocorticoid therapy. Reduced bone formation is the key process in patients with glucocorticoid-induced osteoporosis (GIOP),…
Abstract Number: 2260 • 2014 ACR/ARHP Annual Meeting
Effects of Daily Teriparatide on the Spine and Femoral Strength Assessed By Finite Element Analysis of Clinical Computed Tomography in Rheumatoid Arthritis Patients
Kumiko Ono¹, Satoru Ohashi², Hiroyuki Oka³, Yuho Kadono⁴, Tetsuro Yasui⁴, Yasunori Omata⁴, Naoko Shoda⁴ and Sakae Tanaka¹, ¹Orthopaedic Surgery and Spinal Surgery, The University of Tokyo Hospital, Tokyo, Japan, ²Department of Orthopaedic Surgery, Sagamihara Hospital,National Hospital Organization, Kanagawa, Japan, ³Department of Joint Disease Research, 22nd Century Medical & Research Center, faculty of medicine,the university of Tokyo, Tokyo, Japan, ⁴Department of Orthopaedic Surgery and Spine Surgery, The University of Tokyo Hospital, Tokyo, Japan
Background/Purpose Rheumatoid arthritis (RA) decreases bone mineral density and bone quality, and exposes patients to an increased risk of fracture. In RA treatment, improvement of…
Abstract Number: 2261 • 2014 ACR/ARHP Annual Meeting
A Meta-Anlaysis of Bisphosphonate and Parathyroid Hormone (PTH) Use in Osteoporosis
Zsolt Kulcsar¹, Lena Saleh², Shravani Gangidi³ and Poonam Khadka⁴, ¹Rheumatology/Leadership Preventive Medicine Residency, Dartmouth Hitchcock Medical Center, lebanon, NH, ²The Dartmouth Institute For Healthcare Policy and Clinical Practice, Lebanon, NH, ³The Dartmouth Institute For Healthcare Policy and Clinical Practice, lebanon, NH, ⁴Endocrinology, Dartmouth Hitchcock Medical Center, lebanon, NH
Background/Purpose: Bisphosphonates are currently the drug of choice for treatment of osteoporosis. While anabolic agents like parathyroid hormone (PTH) have shown greater improvements in bone…
Abstract Number: 2262 • 2014 ACR/ARHP Annual Meeting
Raloxifene for Osteoporosis in Postmenopausal Women with Rheumatic Diseases
Won Seok Lee¹, Yun Jung Choi², Yun-Hong Cheon¹, Myong-Joo Hong³, Chang-Hoon Lee⁴, Myeung Su Lee⁴, Sang-Il Lee⁵ and Wan-Hee Yoo⁶, ¹Rheumatology, Department of Internal Medicine, Chonbuk National University Medical School and Research Institute of Clinical Medicine, Jeonju, South Korea, ²Rheumatology, Department of Internal Medicine, Chonbuk National University Medical School and Research Institute of Clinical Medicine, JeonJu, South Korea, ³Department of internal Medicine, Presbyterian Medical center, Jeonju, South Korea, ⁴Department of Internal Medicine, School of Medicine, Wonkwang University, Iksan, Chonbuk, South Korea, ⁵Division of Rheumatology, Department of Internal Medicine, Gyeongsang National University School of Medicine, Jinju, South Korea, ⁶Department of Internal Medicine, Chonbuk National University Medical School and Research Institute of Clinical Medicine, Jeonju, South Korea
Background/Purpose : Raloxifen is a selective estrogen receptor modulator that has been extensively studied. We studied the efficacy of raloxifene on disease activity and bone…
Abstract Number: 2263 • 2014 ACR/ARHP Annual Meeting
Continued Zoledronic Acid Use in a Large Healthcare System
Robert A. Overman¹, Julie C. Lauffenburger², Margaret L. Gourlay³ and Chad L. Deal⁴, ¹Eshelman School of Pharmacy - Division of Pharmaceutical Policy and Outcomes, University of North Carolina, Chapel Hill, NC, ²Division of Pharmaceutical Outcomes and Policy, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, ³Family Medicine, University of North Carolina, Chapel Hill, NC, ⁴Dept of Rheum & Imm Dis /A 50, Cleveland Clinic, Cleveland, OH
Background/Purpose: Oral bisphosphonates adherence has been reported as less than 50% at one year. With patients frequently having refill gaps greater than 30 days. Zoledronic…
Abstract Number: 2264 • 2014 ACR/ARHP Annual Meeting
Denosumab for Long-Term Glucocorticoid Users Who Have Inadequate Response to the Bisphosphonates: A 12-Month Randomized Control Trial
Chi Chiu Mok¹, Ling Yin Ho¹ and Kwok Man Ma², ¹Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong, ²Nuclear Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong
Background/Purpose To evaluate the efficacy of denosumab on bone mineral density (BMD) in long-term glucocorticoid users who have inadequate response to oral bisphosphonate treatment.Methods Patients…
Abstract Number: 2265 • 2014 ACR/ARHP Annual Meeting
Comparative Effects of Raloxifene and Bisphosphonate on Bone Mineral Density and Osteoporotic Fracture Outcomes in Rheumatoid Arthritis Patients
Kowoon Joo¹, Won Park², Seong-Ryul Kwon³, Mie-Jin Lim³ and Kyong-Hee Jung³, ¹Inha University Hospital, Incheon, South Korea, ²Medicine/Rheumatology, Inha University Hospital, Incheon, South Korea, ³Division of Rheumatology, Department of Internal Medicine, Inha University Hospital, Incheon, South Korea
Background/Purpose: Rheumatoid arthritis (RA) accelerates bone loss, increasing the risk of osteoporosis and osteoporotic fractures. We evaluated the effect of raloxifene and bisphosphonate on bone…
Abstract Number: 2266 • 2014 ACR/ARHP Annual Meeting
Risk Factors for Treatment Failure in Osteoporotic Patients with Rheumatoid Arthritis
Kyung-Eun Lee¹, Lihui Wen¹, Dong-Jin Park¹ and Shin-Seok Lee², ¹Rheumatology, Chonnam National University Medical School, Gwangju, South Korea, ²Dept of Int Med/Rheumatology, Chonnam National University Medical School, Gwangju, South Korea
Background/Purpose No available anti-osteoporotic medication has been shown to completely prevent declines in bone mineral density (BMD) and the resulting increased risk of fracture. The…
Abstract Number: 2267 • 2014 ACR/ARHP Annual Meeting
Percentage of Women Achieving Non-Osteoporotic BMD T-Scores at the Spine and Hip over 8 Years of Denosumab Treatment
S. Ferrari¹, C. Libanati², C.J.F Lin², S. Adami³, J.P. Brown⁴, F. Cosman⁵, E. Czerwinski⁶, L.H. de Gregório⁷, J. Malouf⁸, J.-Y. Reginster⁹, N.S. Daizadeh², A. Wang², R.B. Wagman², E.M. Lewiecki¹⁰ and S. Cummings¹¹, ¹Geneva University Hospital, Geneva, Switzerland, ²Amgen Inc., Thousand Oaks, CA, ³University of Verona, Verona, Italy, ⁴Laval University and CHU de Québec Research Centre, Quebec City, QC, Canada, ⁵Helen Hayes Hospital, West Haverstraw, NY, ⁶Krakow Medical Center, Krakow, Poland, ⁷CCBR, Rio de Janeiro, Brazil, ⁸Universitat Autònoma de Barcelona, Barcelona, Spain, ⁹University of Liège, Liège, Belgium, ¹⁰New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM, ¹¹San Francisco Coordinating Center, CPMC Research Institute, and UCSF, San Francisco, CA
Background/Purpose: Guidelines for the treatment of chronic conditions such as hypertension and diabetes include specific biomarker targets. This differs from osteoporosis treatment guidelines, which currently…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].